Drug profile · INN
eprosartan mesylate
TEVETEN
eprosartan mesylate (TEVETEN) is a type-1 angiotensin ii receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — eprosartan mesylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
eprosartan mesylate (TEVETEN) is a type-1 angiotensin ii receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Type-1 angiotensin II receptor antagonist
Primary target: Type-1 angiotensin II receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is eprosartan mesylate?
eprosartan mesylate (TEVETEN) is a type-1 angiotensin ii receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for eprosartan mesylate?
TEVETEN is a marketed brand name for eprosartan mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of eprosartan mesylate?
eprosartan mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.